Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using Lu-iPSMA and Lu-DOTATOC: Experience after 905 Treatment Doses.

Lu-iPSMA is a novel radioligand developed at ININ-Mexico with a high affinity for the PSMA protein heavily expressed in cancer cells of approximately 95% of patients with metastatic castration-resistant prostate cancer (mCRPC). Lu-DOTATOC is a patent-free radioligand, molecularly recognized by somatostatin receptors (SSTR-2) overexpressed in cancer cells of about 80% of patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET). This translational research aimed to determine the efficacy and safety of Lu-iPSMA and Lu-DOTATOC developed as GMP pharmaceutical formulations for treating progressive and advanced mCRPC and NET.

Head to head comparison performance of Tc-EDDA/HYNIC-iPSMA SPECT/CT and Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.

Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) has found widespread use for the diagnosis of biochemical recurrence of prostate cancer (PCa). Unfortunately, PET/CT is not as widely available; thus a PSMA-targeting compound for scintigraphy is of special interest. The aim of this study was to compare Tc-EDDA/HYNIC-iPSMA and Ga-PSMA-11 PET/CT qualitatively and semi-quantitatively.